Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02121418 · ClinicalTrials.gov registry record · NA
Decitabine and Cytarabine in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia, High Risk Myelodysplastic Syndrome, or Myeloproliferative Neoplasm
A NA study of Myelodysplastic Syndrome and Myeloproliferative Neoplasm, sponsored by University of Washington.
- Completed
- Registry status
- NA
- Development phase
- 12
- Enrollment target
- 9
- Study locations
NCT02121418 is a NA study of Myelodysplastic Syndrome and Myeloproliferative Neoplasm that has completed, run by University of Washington. The registered enrollment target is 12 participants, below the 207-participant average among 134 other Myelodysplastic Syndrome trials with a reported enrollment target (94% lower). The trial reports 9 study locations across 2 states.
The verdict
NCT02121418, a NA study of Myelodysplastic Syndrome and Myeloproliferative Neoplasm, has completed, sponsored by University of Washington.
- COMPLETED
- Registry status
- NA
- Development phase
- 12 participants
- Enrollment target
- 9
- Study locations
Study Summary
This clinical trial studies decitabine and cytarabine in treating older patients with newly diagnosed acute myeloid leukemia, myelodysplastic syndrome that is likely to come back or spread to other places in the body, or myeloproliferative neoplasm. Drugs used in chemotherapy, such as decitabine and cytarabine, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving decitabine and cytarabine may work better than standard therapies in treating cancers of the bone marrow and blood cells, such as acute myeloid leukemia, myelodysplastic syndrome, or myeloproliferative neoplasm.
Conditions Studied
Interventions
- DRUG Decitabine
- OTHER Laboratory Biomarker Analysis
- DRUG Cytarabine
Study Locations (9)
Washington
- Kadlec Clinic Hematology and Oncology - Kennewick
- EvergreenHealth Medical Center - Kirkland
- Skagit Valley Hospital - Mount Vernon
- Olympic Medical Center - Port Angeles
- Group Health Cooperative - Redmond
- Fred Hutch/University of Washington Cancer Consortium - Seattle
- Multicare Health System - Tacoma
- Wenatchee Valley Hospital and Clinics - Wenatchee
Montana
- Bozeman Deaconess Hospital - Bozeman
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2014-06 |
| Est. Completion | 2018-02-14 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02121418
The ClinicalTrials.gov registry entry for NCT02121418 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 207-participant average among 134 other Myelodysplastic Syndrome trials with a reported enrollment target (94% lower). The listed sponsor is University of Washington, which has 1,048 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with Myelodysplastic Syndrome appearing as the primary indexed condition, and to 3 interventions - of which Decitabine is the first listed.
NCT02121418 reports 9 study locations spanning 2 distinct geographic areas - top geographies include Washington, Montana.
Frequently Asked Questions
What is clinical trial NCT02121418 about?
NCT02121418 is a clinical study titled "Decitabine and Cytarabine in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia, High Risk Myelodysplastic Syndrome, or Myeloproliferative Neoplasm". This clinical trial studies decitabine and cytarabine in treating older patients with newly diagnosed acute myeloid leukemia, myelodysplastic syndrome that is likely to come back or spread to other places in the body, or myeloproliferative neoplasm. Drugs used in chemotherapy, such as decitabine and...
What is the current status of trial NCT02121418?
This trial is currently completed. It is a NA study. The enrollment target is 12 participants. The study started on 2014-06. Estimated completion is 2018-02-14.
What conditions does trial NCT02121418 study?
This clinical trial studies the following conditions: Myelodysplastic Syndrome, Myeloproliferative Neoplasm, Untreated Adult Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia-2.
What interventions are being tested in trial NCT02121418?
The interventions under investigation include: Decitabine (DRUG), Laboratory Biomarker Analysis (OTHER), Cytarabine (DRUG).
Who is sponsoring clinical trial NCT02121418?
This trial is sponsored by University of Washington, which has 1,048 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02121418 being conducted?
This trial has 9 study locations across Montana, Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Myelodysplastic Syndrome
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Geriatric Optimization Plan to Improve Survival in Older Adult Allogeneic Hematopoietic Cell Transplant Candidates, OTIS Study
ACTIVE NOT RECRUITING · NA
-
A Vaccine (VSV-hIFNβ-NIS) With or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemiplimab in Treating Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia or Lymphoma
RECRUITING · Phase 1
-
Trial of 2 Step ATG for Prevention of Acute GVHD Post Allogeneic Stem Cell Transplant
RECRUITING · Phase 2
-
FHD-286 With Low-Dose Weekly Decitabine/Venetoclax in Patients With Acute Myeloid Leukemia
RECRUITING · Phase 1
-
The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
RECRUITING · Phase 1
-
Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid Tumors
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.